

## ASX ANNOUNCEMENT

27 May 2026

### Investor webinar: BMB18 clinical program and Biome's IP strategy

*Biome Australia Limited* (ASX: BIO) (*Biome* or the *Company*) will host a 30-minute investor webinar on Friday, 5 June 2026 at 9:15am AEST.

The session will cover *Biome's* intellectual property and research strategy, the BMB18 clinical program now underway across La Trobe University (Melbourne) and Harokopio University of Athens (Greece), and the forward IP development plan for the BMB18 strain.

#### Speakers

- Blair Vega Norfolk, Founder and Managing Director
- Lauren Dwyer, Chief Financial Officer

#### Format

20-minute presentation followed by 10 minutes of live Q&A.

Investors and stakeholders will have the opportunity to ask questions during a live Q&A session following the presentation. You may email questions in advance to [corporate@biomeaustralia.com](mailto:corporate@biomeaustralia.com).

#### Webinar Details

**Date:** Friday 5 June 2026

**Time:** 9:15am (AEDT)

[Registration link](#)

Investors are encouraged to register in advance to secure their place.

–ENDS–

Approved for release by the Biome Australia board of directors.

## Investor Hub

*Biome* has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

## About Biome Australia Limited

*Biome Australia* develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: [www.biomeaustralia.com](http://www.biomeaustralia.com)

## Investor Relations

Lauren Dwyer  
[corporate@biomeaustralia.com](mailto:corporate@biomeaustralia.com)  
(03) 9017 5800

## Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of *Biome* (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward



Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.



For personal use only

